Publication Category: Medications
Liraglutide: another reason to target prediabetes?
- C. F. Murphy; N. G. Docherty; C. W. le Roux Liraglutide: another reason to target prediabetes? Oncotarget
Effectiveness and cost of integrating a pragmatic pathway for prescribing liraglutide 3.0 mg in obesity services (STRIVE study): study protocol of an open-label, real-world, randomised, controlled trial
- D. Papamargaritis; W. Al-Najim; J. Lim; J. Crane; M. Lean; C. le Roux; B. McGowan; D. O'Shea; D. Webb; J. Wilding; M. J. Davies Effectiveness and cost of integrating a pragmatic pathway for prescribing liraglutide 3.0 mg in obesity services (STRIVE study): study protocol of an open-label, real-world, randomised, controlled trial BMJ Open
Effects of once-weekly semaglutide vs once-daily canagliflozin on body composition in type 2 diabetes: a substudy of the SUSTAIN 8 randomised controlled clinical trial
- R. J. McCrimmon; A. M. Catarig; J. P. Frias; N. L. Lausvig; C. W. le Roux; D. Thielke; I. Lingvay Effects of once-weekly semaglutide vs once-daily canagliflozin on body composition in type 2 diabetes: a substudy of the SUSTAIN 8 randomised controlled clinical trial Diabetologia
Pioglitazone protects HDL(2&3) against oxidation in overweight and obese men
- J. McEneny; P. A. McPherson; A. McGinty; S. S. Hull; D. R. McCance; I. S. Young Pioglitazone protects HDL(2&3) against oxidation in overweight and obese men Ann Clin Biochem
Adjunctive liraglutide treatment in patients with persistent or recurrent type 2 diabetes after metabolic surgery (GRAVITAS): a randomised, double-blind, placebo-controlled trial
- A. D. Miras; B. Pérez-Pevida; M. Aldhwayan; A. Kamocka; E. R. McGlone; W. Al-Najim; H. Chahal; R. L. Batterham; B. McGowan; O. Khan; V. Greener; A. R. Ahmed; A. Petrie; S. Scholtz; S. R. Bloom; T. M. Tan Adjunctive liraglutide treatment in patients with persistent or recurrent type 2 diabetes after metabolic surgery (GRAVITAS): a randomised, double-blind, placebo-controlled trial Lancet Diabetes Endocrinol
Direct Oral Anticoagulant Concentrations in Obese and High Body Weight Patients: A Cohort Study
-
A. C. Martin; W. Thomas; Z. Mahir; M. P. Crowley; T. Dowling; K. Breen; V. Collings; G. W. Moore; S. MacDonald; B. J. Hunt; A. T. Cohen
Direct Oral Anticoagulant Concentrations in Obese and High Body Weight Patients: A Cohort Study Thromb Haemost
Medications Activating Tubular Fatty Acid Oxidation Enhance the Protective Effects of Roux-en-Y Gastric Bypass Surgery in a Rat Model of Early Diabetic Kidney Disease
- W. P. Martin; Y. H. D. Chuah; M. Abdelaal; A. Pedersen; D. Malmodin; S. Abrahamsson; M. Hutter; C. Godson; E. P. Brennan; L. Fändriks; C. W. le Roux; N. G. Docherty Medications Activating Tubular Fatty Acid Oxidation Enhance the Protective Effects of Roux-en-Y Gastric Bypass Surgery in a Rat Model of Early Diabetic Kidney Disease Front Endocrinol (Lausanne)
The impact of gastrointestinal adverse events on weight loss with liraglutide 3.0 mg as adjunct to a diet and exercise programme
-
C. Le Roux; D. C. W. Lau; K. Fujioka; I. D. Caterson; A. P. Cancino; C. B. Jensen; M. E. J. Lean
The impact of gastrointestinal adverse events on weight loss with liraglutide 3.0 mg as adjunct to a diet and exercise programme Diabetologia
Regulating the effects of GPR21, a novel target for type 2 diabetes
- S. Leonard; G. K. Kinsella; E. Benetti; J. B. Findlay Regulating the effects of GPR21, a novel target for type 2 diabetes Scientific reports